Xin Chen, PhD

Title(s)Professor, Bioengineering
SchoolSchool of Pharmacy
Address513 Parnassus Avenue, HSE
San Francisco CA 94143
Phone415-502-6526
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    1991First Prize Award, Beijing Medical University, Beijing, China
    1998Postdoctoral Fellowship Award, Life Science Research Foundation, Baltimore, MD

    Collapse Overview 
    Collapse Overview
    My lab studies molecular genetics and signaling pathways during hepatic carcinogenesis. Specifically, using genomic approaches including expression arrays and array based CGH, we have identified large numbers of genes which are deregulated during liver cancer development. Using murine models, we are studying how these genetic alterations contribute to malignant transformation and progression in vivo. Our current studies focus on AKT/mTOR and Notch pathways and how they regulate cancer metabolism and cancer cell proliferation. In addition, using the novel mouse models as preclinical models, we are testing the therapeutic potentials of PI3K/mTOR or Notch inhibitors in treating liver cancers.

    Collapse Research 
    Collapse Research Activities and Funding
    Investigating multifactorial beta-catenin activation in hepatocellular cancers
    NIH R01CA250227Jan 7, 2021 - Dec 31, 2025
    Role: Principal Investigator
    Cabozentinib based combination therapy for the treatment of hepatocellular carcinoma
    NIH R03CA249236Apr 1, 2020 - Mar 31, 2022
    Role: Principal Investigator
    Signaling pathways during hepatocarcinogenesis
    NIH R01CA239251Mar 1, 2020 - Feb 28, 2025
    Role: Principal Investigator
    Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
    NIH R01CA228483Jun 19, 2018 - May 31, 2023
    Role: Co-Principal Investigator
    SWI/SNF complex in mouse HCC development
    NIH R03CA208215Aug 1, 2017 - Jul 31, 2020
    Role: Principal Investigator
    Inducible systems for studying liver tumor mainenance in vivo
    NIH R03CA208311Jul 1, 2017 - Jun 30, 2020
    Role: Principal Investigator
    Signaling cascades in cholangiocarcinoma development
    NIH R01CA190606Apr 5, 2016 - Mar 31, 2021
    Role: Principal Investigator
    Yap and beta-catenin interactions in liver: Implications in Pathophysiology
    NIH R01CA204586Apr 5, 2016 - Mar 31, 2021
    Role: Co-Principal Investigator
    Glutamine catabolism in c-Myc driven liver tumor development
    NIH R21CA198490Jun 1, 2015 - May 31, 2018
    Role: Principal Investigator
    Fatty acid transporters in cholangiocarcinoma pathogenesis
    NIH R21CA187306Jul 1, 2014 - Jun 30, 2018
    Role: Principal Investigator
    Lipogenic inhibitors in prevention of oncogene induced liver cancer
    NIH R03CA165122Mar 1, 2012 - Feb 28, 2015
    Role: Principal Investigator
    Virus-gene interactions during hepatic carcinogenesis
    NIH R21CA158508Sep 12, 2011 - Aug 31, 2014
    Role: Principal Investigator
    Genetic Alterations Promoting Alcohol Induced Hepatic Carcinogenesis
    NIH R21AA020078Sep 1, 2011 - Aug 31, 2014
    Role: Principal Investigator
    Targeted siRNA Delivery to Liver with EIT guided Sonoporation
    NIH R43AA019638Sep 30, 2009 - Mar 31, 2011
    Role: Co-Principal Investigator
    Molecular Genetics of Liver Cancers
    NIH R01CA136606May 1, 2009 - Feb 28, 2019
    Role: Principal Investigator
    A flexible somatic and sporadic mouse model for liver cancers
    NIH R21CA131625Jul 1, 2008 - Jun 30, 2011
    Role: Principal Investigator
    Expression Programs of Intestinal Cell Differentiation
    NIH R21DK069309Sep 15, 2005 - Aug 31, 2008
    Role: Principal Investigator
    Hedgehog signaling in human hepatocellular carcinoma
    NIH R21CA113393Jul 1, 2005 - Jun 30, 2008
    Role: Principal Investigator
    Expression patterns of gastric premalignant lesions
    NIH R03CA112638Sep 30, 2004 - Aug 31, 2007
    Role: Principal Investigator
    Gene Expression Profiles in Human Liver Cancers
    NIH K01CA096774Sep 11, 2003 - Aug 31, 2009
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Identifying strategies to target the metabolic flexibility of tumours. Nat Metab. 2020 04; 2(4):335-350. Méndez-Lucas A, Lin W, Driscoll PC, Legrave N, Novellasdemunt L, Xie C, Charles M, Wilson Z, Jones NP, Rayport S, Rodríguez-Justo M, Li V, MacRae JI, Hay N, Chen X, Yuneva M. PMID: 32694609; PMCID: PMC7436715.
      View in: PubMed   Mentions: 16  Translation:HumansAnimals
    2. Mammalian Target of Rapamycin Complex 2 Signaling Is Required for Liver Regeneration in a Cholestatic Liver Injury Murine Model. Am J Pathol. 2020 07; 190(7):1414-1426. Zhou Y, Xu M, Liu P, Liang B, Qian M, Wang H, Song X, Nyshadham P, Che L, Calvisi DF, Li F, Lin S, Chen X. PMID: 32275903; PMCID: PMC7341974.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    3. Publisher Correction: Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020 Mar 11. Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. PMID: 32161375; PMCID: PMC7483291.
      View in: PubMed   Mentions:    Fields:    
    4. Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell Death Dis. 2020 02 04; 11(2):91. Wang P, Song X, Cao D, Cui K, Wang J, Utpatel K, Shang R, Wang H, Che L, Evert M, Zhao K, Calvisi DF, Chen X. PMID: 32019910; PMCID: PMC7000409.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    5. SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model. Cancer Res. 2019 11 01; 79(21):5563-5574. Xu M, Wang J, Xu Z, Li R, Wang P, Shang R, Cigliano A, Ribback S, Solinas A, Pes GM, Evert K, Wang H, Song X, Zhang S, Che L, Pascale RM, Calvisi DF, Liu Q, Chen X. PMID: 31383647; PMCID: PMC7237201.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    6. The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans. Hepatology. 2019 11; 70(5):1600-1613. Xu Z, Xu M, Liu P, Zhang S, Shang R, Qiao Y, Che L, Ribback S, Cigliano A, Evert K, Pascale RM, Dombrowski F, Evert M, Chen X, Calvisi DF, Chen X. PMID: 31062368; PMCID: PMC7195156.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    7. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. J Hepatol. 2019 10; 71(4):742-752. Wang J, Wang H, Peters M, Ding N, Ribback S, Utpatel K, Cigliano A, Dombrowski F, Xu M, Chen X, Song X, Che L, Evert M, Cossu A, Gordan J, Zeng Y, Chen X, Calvisi DF. PMID: 31195063; PMCID: PMC6773530.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    8. Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice. Hepatology. 2019 12; 70(6):2003-2017. Qiao Y, Wang J, Karagoz E, Liang B, Song X, Shang R, Evert K, Xu M, Che L, Evert M, Calvisi DF, Tao J, Wang B, Monga SP, Chen X. PMID: 30737831; PMCID: PMC7206928.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    9. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020 01; 69(1):177-186. Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, Li L, Jia J, Pilo MG, Wang J, Cigliano A, Ma Z, Kuang W, Tang Z, Zhang Z, Shui G, Ribback S, Dombrowski F, Evert M, Pascale RM, Cossu C, Pes GM, Osborne TF, Calvisi DF, Chen X, Chen L. PMID: 30954949; PMCID: PMC6943247.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    10. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. 2018 06; 37(24):3229-3242. Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X. PMID: 29545603; PMCID: PMC6002343.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    11. Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans. Am J Pathol. 2018 04; 188(4):995-1006. Zhang S, Wang J, Wang H, Fan L, Fan B, Zeng B, Tao J, Li X, Che L, Cigliano A, Ribback S, Dombrowski F, Chen B, Cong W, Wei L, Calvisi DF, Chen X. PMID: 29378174; PMCID: PMC5866106.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    12. Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death Dis. 2018 01 18; 9(2):31. Dong M, Liu X, Evert K, Utpatel K, Peters M, Zhang S, Xu Z, Che L, Cigliano A, Ribback S, Dombrowski F, Cossu A, Gordan J, Calvisi DF, Evert M, Liu Y, Chen X. PMID: 29348467; PMCID: PMC5833851.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    13. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. Exp Mol Med. 2018 01 05; 50(1):e417. Xu Z, Hu J, Cao H, Pilo MG, Cigliano A, Shao Z, Xu M, Ribback S, Dombrowski F, Calvisi DF, Chen X. PMID: 29303510; PMCID: PMC5992985.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    14. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. J Hepatol. 2017 12; 67(6):1194-1203. Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, Hu J, Chen B, Dong M, Pilo MG, Cigliano A, Evert K, Ribback S, Dombrowski F, Pascale RM, Cossu A, Vidili G, Porcu A, Simile MM, Pes GM, Giannelli G, Gordan J, Wei L, Evert M, Cong W, Calvisi DF, Chen X. PMID: 28733220; PMCID: PMC5696057.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    15. Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities. Cancer Res. 2017 08 15; 77(16):4355-4364. Méndez-Lucas A, Li X, Hu J, Che L, Song X, Jia J, Wang J, Xie C, Driscoll PC, Tschaharganeh DF, Calvisi DF, Yuneva M, Chen X. PMID: 28630053; PMCID: PMC5559320.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    16. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology. 2017 07; 66(1):167-181. Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, Cigliano A, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Tao J, Calvisi DF, Chen L, Chen X. PMID: 28370287; PMCID: PMC5481473.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    17. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver Int. 2017 01; 37(1):80-89. Cao D, Song X, Che L, Li X, Pilo MG, Vidili G, Porcu A, Solinas A, Cigliano A, Pes GM, Ribback S, Dombrowski F, Chen X, Li L, Calvisi DF. PMID: 27264722; PMCID: PMC5140766.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    18. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology. 2016 06; 63(6):1900-13. Li L, Che L, Tharp KM, Park HM, Pilo MG, Cao D, Cigliano A, Latte G, Xu Z, Ribback S, Dombrowski F, Evert M, Gores GJ, Stahl A, Calvisi DF, Chen X. PMID: 26910791; PMCID: PMC4874885.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    19. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Sci Rep. 2016 Feb 09; 6:20484. Hu J, Che L, Li L, Pilo MG, Cigliano A, Ribback S, Li X, Latte G, Mela M, Evert M, Dombrowski F, Zheng G, Chen X, Calvisi DF. PMID: 26857837; PMCID: PMC4746674.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    20. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J Hepatol. 2016 Feb; 64(2):333-341. Li L, Pilo GM, Li X, Cigliano A, Latte G, Che L, Joseph C, Mela M, Wang C, Jiang L, Ribback S, Simile MM, Pascale RM, Dombrowski F, Evert M, Semenkovich CF, Chen X, Calvisi DF. PMID: 26476289; PMCID: PMC4718802.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    Xin's Networks
    Concepts (105)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (3)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-871-g21b54b14 on PROFILES-PWEB01.

    Copyright © The Regents of the University of California